NCT05675033 2023-01-09
Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
Fujian Cancer Hospital
Phase 2 Unknown
Clinical Trials
5 trialsNCT02621333 2021-05-12
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
Henan Cancer Hospital
Phase 2 Terminated
NCT02737774 2020-07-01
Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
Henan Cancer Hospital
Phase 2 Unknown
NCT03486496 2018-04-03
Geber
Fujian Cancer Hospital
Phase 2 Unknown
NCT01502202 2012-06-20
Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
National Cancer Center, Korea
Phase 2 Unknown